An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →
Athernal Bio receives £700k grant from Innovate UK to expand R&D in targeted immunotherapies for cancer interception.
Sep 15, 2026•1 day ago
CambridgeBiotechnologyHealth Care
Description
Athernal Bio, a Cambridge-based immunotherapy company, received a £700k grant through Innovate UK's Growth Catalyst – Investor Partnerships programme. The funding, backed by existing investor Delin Ventures, will support the expansion of operations and R&D efforts. The company develops targeted immunotherapies to treat blood cancer precursor conditions, specifically focusing on high-risk clonal haematopoiesis to prevent progression into acute myeloid leukaemia.
Company Information
Company
Athernal Bio
Location
Cambridge, England, United Kingdom
About
Athernal Bio is developing targeted immunotherapies to treat blood cancer precursor conditions before cancers become established. The company’s primary focus is high-risk clonal haematopoiesis (CH), a widespread cancer precursor condition which can lead to acute myeloid leukaemia and other haematological cancers. High-risk CH affects multiple groups, including patients with rare blood disorders, cancer survivors, and the ageing population. Athernal Bio’s initial programme is an immunotherapy for patients with inherited rare blood disorders, associated with the most aggressive and highly accelerated forms of CH. Athernal Bio has built a strong team, supported by renowned advisors across the US and Europe, to rapidly develop the first therapeutic options for early intervention in patients with high-risk CH, aiming to stop cancer before it starts.
Predictive Intelligence
Strategic
ML-powered predictions for Athernal Bio's next move
CambridgeBiotechnologyHealth Care